Synageva BioPharma Overview
- Founded
- 1996

- Status
- Acquired/Merged
- Employees
- 282

- Latest Deal Type
- M&A
- Financing Rounds
- 14
- Investments
- 1
Synageva BioPharma General Information
Description
Developer of medicines for rare diseases. The company's focus is on developing, delivering and commercializing products for rare diseases.
Contact Information
- 33 Hayden Avenue
- Lexington, MA 02421
- United States
Synageva BioPharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Synageva BioPharma‘s full profile, request access.
Request a free trialSynageva BioPharma Comparisons
Industry

00000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialSynageva BioPharma Competitors (7)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Santhera Pharmaceuticals | Formerly VC-backed | Switzerland | 00 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
000000 00000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
0000000000 0000000 | Formerly VC-backed | Novato, CA | 0000 | 00000 | 000000000 | 00000 |
Synageva BioPharma Patents
Synageva BioPharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20130330317-A1 | Methods for treating lysosomal acid lipase deficiency | Abandoned | 15-Feb-2012 | 0000000000 | |
AU-2012322811-A1 | Recombinant human naglu protein and uses thereof | Abandoned | 12-Oct-2011 | 000000000 | |
CA-2852027-A1 | Recombinant human naglu protein and uses thereof | Abandoned | 12-Oct-2011 | 000000000 | |
US-20140255383-A1 | Recombinant human naglu protein and uses thereof | Abandoned | 12-Oct-2011 | 000000000 | |
JP-6329483-B2 | Recombinant human naglu protein and use thereof | Active | 12-Oct-2011 | A61K38/47 |
Synageva BioPharma Executive Team (15)
Synageva BioPharma Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSynageva BioPharma Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Synageva BioPharma‘s full profile, request access.
Request a free trialSynageva BioPharma Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 | 03-Nov-2011 | 0000000000 | 00000 | Medical Supplies | 0000 0000 |